Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SIMPESSE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
Oral: 10 mg once daily, taken at least 1 hour before a meal.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Metabolized via cytochrome P450 enzymes (CYP3A4) in the liver; ethinyl estradiol undergoes sulfation and glucuronidation; levonorgestrel is conjugated and excreted in urine and feces.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
95% bound primarily to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
0.8 L/kg, indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 90%; intravenous: 100%.
Oral: ~70% due to first-pass metabolism.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 5 mg once daily. GFR <30 m L/min: Not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not approved for use in pediatric patients (<18 years).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment recommended; monitor renal function and consider age-related decline in GFR.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Carcinoma of the breast and reproductive organs,Liver disease (hepatic adenomas, hepatocellular carcinoma),Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache/migraine,Uterine bleeding irregularities,Depression,Contact lens intolerance
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Current or past history of cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy (Category X),Heavy smoking (≥15 cigarettes/day) in women over 35 years of age
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit and grapefruit juice may increase plasma levels of SIMPESSE, potentiating its hypotensive and bradycardic effects. Avoid concurrent intake. No other significant food interactions are established.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy Category X. First trimester: Major congenital malformations including craniofacial defects, CNS abnormalities, and cardiovascular defects. Second/third trimesters: Increased risk of spontaneous abortion, preterm labor, and intrauterine growth restriction. Contraindicated in pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated in breastfeeding. M/P ratio not established; drug is present in human milk and may cause serious adverse effects in nursing infants. Discontinue nursing or drug.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Not applicable; drug is contraindicated in pregnancy. No dose adjustment studies exist due to absolute contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
SIMPESSE is a non-selective beta-blocker indicated for acute management of supraventricular tachyarrhythmias. Monitor for hypotension, bradycardia, and bronchospasm, especially in asthmatics. Contraindicated in decompensated heart failure, cardiogenic shock, and severe sinus node dysfunction. Administer slow IV push over 1-2 minutes to reduce risk of adverse effects.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
This medication is given intravenously and requires continuous heart rate and blood pressure monitoring.,You may experience dizziness, lightheadedness, or shortness of breath. Report these to your healthcare provider immediately.,Avoid sudden position changes to prevent falls due to low blood pressure.,If you have asthma or COPD, inform your provider before treatment.,Do not consume grapefruit or grapefruit juice during treatment as it may increase side effects.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SIMPESSE vs AFIRMELLE, answered by our medical review team.
SIMPESSE is a Oral Contraceptive that works by Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SIMPESSE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SIMPESSE is: Oral: 10 mg once daily, taken at least 1 hour before a meal.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SIMPESSE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SIMPESSE is classified as Category C. Pregnancy Category X. First trimester: Major congenital malformations including craniofacial defects, CNS abnormalities, and cardiovascular defects. Second/third trimesters: Increa. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.